Methylphenidat Stada

Methylphenidate Hydrochloride, the active ingredient in Methylphenidat Stada, is a central nervous system stimulant presented as an oral formulation for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults. By inhibiting the reuptake of dopamine and norepinephrine, it raises their synaptic concentrations, which helps improve focus and reduce excessive daytime sleepiness.

GNH USA supplies Methylphenidat Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing consistent quality, regulatory compliance, and reliable logistics for global distribution.

Methylphenidate Hydrochloride is a central nervous system stimulant used in the management of neurobehavioral disorders. - Attention deficit hyperactivity disorder (ADHD): improves attention, reduces hyperactivity and impulsivity in children, adolescents, and adults. - Narcolepsy: decreases excessive daytime sleepiness and improves wakefulness. - ADHD in adults: enhances occupational performance and daily functioning. - ADHD in children: supports academic performance and behavior control.

Methylphenidate Hydrochloride may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Irritability: increased mood swings or agitation.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, hypertension, or arrhythmia. - Psychosis or severe agitation: hallucinations or extreme behavioral changes. - Allergic reactions: rash, swelling, or anaphylaxis.

When prescribing Methylphenidate Hydrochloride, clinicians should consider several safety precautions. - Cardiovascular assessment: evaluate heart disease history and blood pressure before initiation. - Psychiatric monitoring: observe for mood swings, anxiety, or emergence of psychotic symptoms. - Growth monitoring: regularly track height and weight in pediatric patients. - Abuse potential: use only as directed due to risk of dependence. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methylphenidate Hydrochloride can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may cause hypertensive crisis. - Antihypertensive agents: may reduce blood pressure control. - Antipsychotics: can diminish stimulant effect and increase side effects.

Moderate Interactions (Monitor Closely): - SSRIs and SNRIs: may increase risk of serotonin syndrome. - CYP2D6 inhibitors: can raise methylphenidate plasma levels.